(NASDAQ: KYTX) Kyverna Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Kyverna Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast KYTX's revenue for 2027 to be $185,841,154, with the lowest KYTX revenue forecast at $185,841,154, and the highest KYTX revenue forecast at $185,841,154. On average, 1 Wall Street analysts forecast KYTX's revenue for 2028 to be $1,711,467,371, with the lowest KYTX revenue forecast at $1,711,467,371, and the highest KYTX revenue forecast at $1,711,467,371.
In 2029, KYTX is forecast to generate $6,824,260,047 in revenue, with the lowest revenue forecast at $6,824,260,047 and the highest revenue forecast at $6,824,260,047.